Abstract
Abstract Objectives Helicobacter pylori (H. pylori) is the leading cause of chronic gastritis and gastric ulcers and significantly increases the risk of developing gastric cancer. Even though many therapeutic improvements in H. pylori eradication rate, it is still associated with the high prevalence of infection. Several studies have verified that probiotics treatment were beneficial to gastrointestinal tract infections is increasingly documented as an alternative to antibiotics. This study aimed to investigate the efficacy of novelty probiotic complex on H. pylori infection in patients. Methods Between October 2018 and August 2019, all subjects with a clinical of Chung Shan Medical University Hospital in Taiwan, subjects who confirmed H. pylori infection (n = 20) were randomized to receive probiotic complex or placebo for 3 weeks. The probiotic complex contained Lactobacillus johnsonii No.1088 (HK-LJ88) 1010 CFU/mL, Bacillus subtilis 1012 CFU/mL, green tea extract and sake lees. Primary outcome of this study was The amounts of change of 13C urea breath test (13C UBT) that was assessed 3 weeks after the end of supplementation. The hematological results, dietary records, anthropogenic indicators were measured/assessed at the 0 and 3th week. Results Subjects in the probiotic group had significantly lower 13C UBT (39.6%) at the 3th week when compared to the value at week 0. In contrast with subjects in the placebo group had higher 50% 13C UBT. The levels of anthropometric indices, blood glucose and lipid profiles had no significant changes during the intervention study period in both groups. After adjusting for age and gender, supplement had significant effect on reducing the change of 13C UBT (β = -13.64, p = 0.047) and diastolic blood pressure (β = -6.91, p = 0.03). Conclusions These results suggest that supplement with the combination of probiotic Lactobacillus johnsonii and Bacillus subtilis for 3 weeks may have a favorable effect on H. pylori infection in humans. The probiotics intervention also resulted in improved blood pressure. Funding Sources Yang Ming Biomed Co., Ltd.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.